{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:33:55Z","timestamp":1753875235535,"version":"3.41.2"},"reference-count":31,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012112","name":"Sobi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Hematology"],"published-print":{"date-parts":[[2024,12,31]]},"DOI":"10.1080\/16078454.2024.2320610","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T13:31:17Z","timestamp":1709731877000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["An observational study of haemophilia A patients without inhibitors using the French national claims (SNDS) database"],"prefix":"10.1080","volume":"29","author":[{"given":"Marc","family":"Trossa\u00ebrt","sequence":"first","affiliation":[{"name":"Hemophilia Treatment Centre, University Hospital of Nantes, Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aletta","family":"Falk","sequence":"additional","affiliation":[{"name":"Global Medical Affairs and Clinical Science, Sobi, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laur\u00e8ne","family":"Gautier","sequence":"additional","affiliation":[{"name":"Real World Evidence Data and Analytics, Cerner Enviza, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nana","family":"Kragh","sequence":"additional","affiliation":[{"name":"Global Health Economics and Outcomes Research, Sobi, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Van Hinloopen","sequence":"additional","affiliation":[{"name":"Patient Access, Sobi, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remi","family":"Varin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Rouen University Hospital, Rouen, France"},{"name":"UNIROUEN, INSERM U1234, Pathophysiology, Autoimmunity, Neuromuscular Diseases and Regenerative THERapies, Normandie University, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/M19-1208"},{"key":"e_1_3_5_3_1","unstructured":"FranceCoag. National statistics - demographic: haemophilia A 2023 [cited 2023 Jan 20]. Available from: https:\/\/francecoag.org\/SiteWebPublic\/public\/stats\/stats_page.jsp?stat2\u2009=\u2009on."},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12672"},{"key":"e_1_3_5_6_1","unstructured":"Minist\u00e8re de la sant\u00e9 et de la pr\u00e9vention - base de donn\u00e9es publique des m\u00e9dicaments. Factane - Summary of Product Characteristics [cited 2023 Jan 24]. Available from: https:\/\/base-donnees-publique.medicaments.gouv.fr\/affichageDoc.php?specid\u2009=\u200966716833&typedoc\u2009=\u2009R"},{"key":"e_1_3_5_7_1","unstructured":"European Medicines Agency. Advate - summary of product characteristics [cited 2023 Jan 24]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/advate-epar-product-information_en.pdf."},{"key":"e_1_3_5_8_1","unstructured":"European Medicines Agency. Elocta - summary of product characteristics. 2019 [cited 2022 March]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elocta-epar-product-information_en.pdf."},{"key":"e_1_3_5_9_1","unstructured":"Haute Authorit\u00e9 de Sant\u00e9. Adynovi (rurioctocog alfa pegol). Commission de le Transparence Avis 10 avril 2019 [cited 2023 June 20]. Available from: https:\/\/www.has-sante.fr\/jcms\/c_2965047\/en\/adynovi-rurioctocog-alfa-pegol."},{"key":"e_1_3_5_10_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Jivi (damoctacog alfa pegol). Commission de la Transparence Avis 5 juin 2019 [cited 2023 June 20]. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/evamed\/CT-17559_JIVI_PIC_INS_Avis3_CT17559.pdf."},{"key":"e_1_3_5_11_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Esperoct (turoctocog alfa pegol). Commission de la Transparence Avis 10 mars 2021 [cited 2023 June 20]. Available from: https:\/\/www.has-sante.fr\/jcms\/p_3242180\/en\/esperoct-turoctocog-alfa-pegol."},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4233"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13824"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-021-00259-2"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14649"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.respe.2017.05.004"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-021-01339-4"},{"key":"e_1_3_5_18_1","unstructured":"Dispositif FranceCoag. Cohorte fran\u00e7aise des patients vivant avec une maladie hemorragique constitutionnelle. Donn\u00e9es descriptives au 31 d\u00e9cembre 2021 2022. Available from: https:\/\/francecoag.org\/SiteWebPublic\/pdfs\/rapports_annuels_publics\/2021_Rapport_annuel_FC.pdf."},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13111"},{"key":"e_1_3_5_20_1","unstructured":"R\u00e9seau FranceCoag. Cohorte fran\u00e7aise des patients atteints de maladies h\u00e9morragiques par d\u00e9ficits h\u00e9r\u00e9ditaires en prot\u00e9ines de la coagulation - Donn\u00e9es descriptives 2005 2005 [cited 2023 Jan 24]. Available from: https:\/\/www.vie-publique.fr\/sites\/default\/files\/rapport\/pdf\/064000522.pdf."},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14316"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13834"},{"key":"e_1_3_5_23_1","unstructured":"European Medicines Agency. Kovaltry - summary of product characteristics [cited 2023 Jan 24]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kovaltry-epar-product-information_en.pdf."},{"key":"e_1_3_5_24_1","unstructured":"European Medicines Agency. Helixate NextGen - summary of product characteristics [cited 2023 Jan 24]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/helixate-nexgen-epar-product-information_en.pdf."},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1991901"},{"issue":"5","key":"e_1_3_5_26_1","first-page":"374","article-title":"Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience","volume":"18","author":"Tagliaferri A","year":"2020","unstructured":"Tagliaferri A, Matichecchia A, Rivolta GF, et al. Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience. Blood Transfus. 2020;18(5):374\u2013385.","journal-title":"Blood Transfus"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-92245-5"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.15520\/jcmro.v4i05.422"},{"issue":"1","key":"e_1_3_5_29_1","first-page":"79","article-title":"Recombinant factor VIII Fc showed better prophylactic effectiveness compared to standard half-life factor VIII in haemophilia A \u2013results from A-SURE, a 24-month prospective, non-interventional study","volume":"6","author":"Oldenburg J","year":"2022","unstructured":"Oldenburg J, Hay C, Peyvandi F, et al. Recombinant factor VIII Fc showed better prophylactic effectiveness compared to standard half-life factor VIII in haemophilia A \u2013results from A-SURE, a 24-month prospective, non-interventional study. Res Pract Thromb Haemost. 2022;6(S1):79\u201380.","journal-title":"Res Pract Thromb Haemost"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000885"},{"key":"e_1_3_5_31_1","unstructured":"ClinicalTrials.gov. Study identifier NCT04293523. A 48-month study to evaluate long-term effectiveness of elocta on joint health (A-MORE) [cited 2023 May 30]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04293523."},{"key":"e_1_3_5_32_1","unstructured":"ClinicalTrials.gov. Study identifier NCT03055611. A study to evaluate real-world usage and effectiveness of Elocta and Alprolix in patients with Haemophilia A or B (PREVENT) [cited 2023 May 30]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03055611."}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/16078454.2024.2320610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T15:11:41Z","timestamp":1734016301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/16078454.2024.2320610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,31]]}},"alternative-id":["10.1080\/16078454.2024.2320610"],"URL":"https:\/\/doi.org\/10.1080\/16078454.2024.2320610","relation":{},"ISSN":["1607-8454"],"issn-type":[{"type":"electronic","value":"1607-8454"}],"subject":[],"published":{"date-parts":[[2024,3,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhem20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=yhem20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-08-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2320610"}}